Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.
Journal: Gynecologic oncology
Published: March 24, 2026
Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 04, 2026
GlycoKnow Ovarian: a Glycoprotein-based, Serum Diagnostic to Distinguish Ovarian Cancers from Benign Pelvic Masses.
Journal: medRxiv : the preprint server for health sciences
Published: July 15, 2025
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial.
Journal: Gynecologic oncology
Published: February 04, 2025
A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel.
Journal: Therapeutic advances in medical oncology
Published: December 20, 2024
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".
Journal: Future oncology (London, England)
Published: July 11, 2024
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Journal: Therapeutic advances in medical oncology
Published: May 21, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: March 08, 2024
The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study.
Journal: Gynecologic oncology
Published: December 22, 2023
A case report of pulmonary alveolar microlithiasis with pulmonary tuberculosis.
Journal: Lung India : official organ of Indian Chest Society
Published: April 03, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Journal: The New England journal of medicine
Published: March 27, 2023
Last Updated: 09/26/2026